Literature DB >> 23891537

Metabolism and energy requirements in pantothenate kinase-associated neurodegeneration.

Sarah Williams1, Allison Gregory, Penelope Hogarth, Susan J Hayflick, Melanie B Gillingham.   

Abstract

Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive disorder of coenzyme A homeostasis caused by defects in the mitochondrial pantothenate kinase 2. Patients with PKAN present with a progressive neurological decline and brain iron accumulation, but general energy balance and nutrition status among these patients has not been reported. To determine if defects in PANK2 change basic energy metabolism in humans, we measured body composition, resting energy expenditure, dietary intake, and blood metabolites among 16 subjects with PKAN. Subjects had a broad range of disease severity but, despite the essential role of coenzyme A in energy metabolism, the subjects had remarkably normal body composition, dietary intake and energy metabolism compared to population normal values. We did observe increased resting energy expenditure associated with disease severity, suggesting increased energy needs later in the disease process, and elevated urinary mevalonate levels.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coenzyme A; Hallervorden–Spatz syndrome; PKAN; Pantothenate kinase-associated neurodegeneration; Resting energy expenditure

Mesh:

Substances:

Year:  2013        PMID: 23891537      PMCID: PMC6059611          DOI: 10.1016/j.ymgme.2013.06.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  The Diet Habit Survey: a new method of dietary assessment that relates to plasma cholesterol changes.

Authors:  S L Connor; J R Gustafson; G Sexton; N Becker; S Artaud-Wild; W E Connor
Journal:  J Am Diet Assoc       Date:  1992-01

2.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome.

Authors:  B Zhou; S K Westaway; B Levinson; M A Johnson; J Gitschier; S J Hayflick
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

3.  Reliability and responsiveness of the Barry-Albright Dystonia Scale.

Authors:  M J Barry; J M VanSwearingen; A L Albright
Journal:  Dev Med Child Neurol       Date:  1999-06       Impact factor: 5.449

4.  Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys.

Authors:  W E Connor; M Neuringer; D S Lin
Journal:  J Lipid Res       Date:  1990-02       Impact factor: 5.922

5.  Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations.

Authors:  Valerio Leoni; Laura Strittmatter; Giovanna Zorzi; Federica Zibordi; Sabrina Dusi; Barbara Garavaglia; Paola Venco; Claudio Caccia; Amanda L Souza; Amy Deik; Clary B Clish; Marco Rimoldi; Emilio Ciusani; Enrico Bertini; Nardo Nardocci; Vamsi K Mootha; Valeria Tiranti
Journal:  Mol Genet Metab       Date:  2011-12-14       Impact factor: 4.797

6.  Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome).

Authors:  Robert A Egan; Richard G Weleber; Penelope Hogarth; Allison Gregory; Jason Coryell; Shawn K Westaway; Jane Gitschier; Soma Das; Susan J Hayflick
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

7.  Validation of a care and comfort hypertonicity questionnaire.

Authors:  Robin Nemer McCoy; Peter A Blasco; Barry S Russman; Jean P O'Malley
Journal:  Dev Med Child Neurol       Date:  2006-03       Impact factor: 5.449

8.  HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration.

Authors:  K H L Ching; S K Westaway; J Gitschier; J J Higgins; S J Hayflick
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

9.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Authors:  Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

10.  Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model.

Authors:  Dario Brunetti; Sabrina Dusi; Michela Morbin; Andrea Uggetti; Fabio Moda; Ilaria D'Amato; Carla Giordano; Giulia d'Amati; Anna Cozzi; Sonia Levi; Susan Hayflick; Valeria Tiranti
Journal:  Hum Mol Genet       Date:  2012-09-13       Impact factor: 6.150

View more
  3 in total

1.  Quantitative susceptibility-weighted imaging in amyotrophic lateral sclerosis with 3.0 T magnetic resonance imaging.

Authors:  Meng-Yu Liu; Zhi-Ye Chen; Jin-Feng Li; Hua-Feng Xiao; Lin Ma
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

2.  Induction of Neuron-Specific Degradation of Coenzyme A Models Pantothenate Kinase-Associated Neurodegeneration by Reducing Motor Coordination in Mice.

Authors:  Stephanie A Shumar; Paolo Fagone; Adolfo Alfonso-Pecchio; John T Gray; Jerold E Rehg; Suzanne Jackowski; Roberta Leonardi
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

3.  Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN.

Authors:  Yiolanda-Panayiota Christou; George A Tanteles; Elena Kkolou; Annita Ormiston; Kostas Konstantopoulos; Maria Beconi; Randall D Marshall; Horacio Plotkin; Kleopas A Kleopa
Journal:  Case Rep Neurol Med       Date:  2017-04-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.